CellFE®, a disruptive life sciences company marketing non-viral, non-electroporative cell therapy manufacturing tools, today announced several strategic system placements with major pharmaceutical and ...

Researchers have developed lipid nanoparticles (LNPs) that cross the blood-brain barrier (BBB) and precisely target brain cells, a major step toward treating neurological diseases like Alzheimer’s.

In this manuscript, Yao et al. present solid evidence to show that MnMYL3 may serve as a receptor for NNV via macropinocytosis. This manuscript is valuable for understanding the molecular mechanisms ...